IL2 and lymphoma: Antibody targeting of IL2 to the lymphoma-associated subendothelial extracellular matrix of the neo-vasculature accumulated IL2 in the lymphoma lesions after systemic application resulting in improved anti-tumor activity compared with un-conjugated IL2 [29].